ImmunityBio, Inc. filings document the formal reporting record for a commercial-stage immunotherapy company with Nasdaq-listed common stock. Form 8-K reports furnish operating results, ANKTIVA product revenue updates, regulatory authorizations for ANKTIVA with BCG in NMIBC, FDA promotional-compliance correspondence, and material agreements including revenue interest purchase agreement amendments and convertible promissory note amendments.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data, and shareholder voting matters. The filings also describe capital structure and financing obligations, related-party arrangements, and risk factors tied to clinical development, regulatory review, manufacturing and supply, commercialization, reimbursement, competition, and market acceptance.
ImmunityBio director Linda Maxwell received a stock option grant on June 18, 2025, representing a significant insider transaction. The details include:
- Granted 162,786 stock options to purchase common stock
- Exercise price set at $2.84 per share
- Options expire on June 18, 2035
- 100% vesting occurs at earlier of June 18, 2026 or day before next annual stockholder meeting
- Vesting conditional on continued service as defined in 2025 Equity Incentive Plan
This Form 4 filing represents standard board of director equity compensation. The direct ownership structure and 10-year option term align with typical corporate governance practices for director incentivization.
ImmunityBio director Wesley Clark received a stock option grant on June 18, 2025, according to a Form 4 filing. The derivative securities transaction details include:
- Granted 162,786 stock options to purchase common stock
- Exercise price set at $2.84 per share
- Options expire on June 18, 2035
- 100% vesting occurs at earlier of June 18, 2026 or day before next annual stockholder meeting
- Vesting conditional on continued service as defined in 2025 Equity Incentive Plan
The filing indicates direct ownership of these options by Clark, who serves as a Director of ImmunityBio. This equity compensation grant aligns with standard board member compensation practices and aims to align the director's interests with shareholders.
ImmunityBio, Inc. (NASDAQ: IBRX) filed an 8-K to report the results of its 2025 Annual Meeting held on 18 June 2025 and the adoption of a new share-based compensation program.
Equity Incentive Plan: Stockholders approved the 2025 Equity Incentive Plan, which immediately replaces the 2015 plan scheduled to expire in July 2025. The new plan reserves 46,088,027 new shares of common stock and allows recycling of up to 32,359,674 shares from previously granted but forfeited or expired awards under the 2015 plan. In total, up to roughly 78 million shares (≈ 8.8 % of shares outstanding) could be issued over time, subject to customary anti-dilution adjustments.
Governance Matters: • A strong quorum was achieved with 785,427,063 shares (≈ 89 % of outstanding) represented.
• All eight incumbent directors—including Executive Chairman Patrick Soon-Shiong, M.D.—were re-elected. “For” votes ranged from 695.2 million to 700.9 million, with minimal opposition and 81.7 million broker non-votes.
• The 2025 Equity Incentive Plan garnered 684.0 million votes “For” (≈ 96 % of votes cast, excluding broker non-votes).
• Deloitte & Touche LLP was ratified as auditor for fiscal 2025 with 781.3 million votes “For” (≈ 99 %).
Strategic Rationale: The Board states the new plan is intended to enhance ImmunityBio’s ability to attract, retain, and motivate key talent by providing equity-based incentives that align employee and shareholder interests. No additional awards will be granted under the 2015 plan, but existing awards will continue to be governed by it.
No financial performance metrics, earnings data, or major transactions were disclosed in this filing. The only exhibit filed is the full text of the 2025 Equity Incentive Plan (Exhibit 10.1).